Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of sonodynamic therapy with ExAblate MRI-guided focused ultrasound plus 5-ALA in cerebral glioblastoma
2021-003374-30Phase 2Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 5-aminolevulinic acid in glioblastoma (GBM), sponsored by Carlo Besta Neurological Institute. Primary endpoints: Safety and Feasibility. Started Oct 2021; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2021-003374-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003374-30.